Publications

Filters
February 7, 2025

Cancer target back in contention with more selective inhibitor

Read more
December 14, 2024

Site-selective template-directed synthesis of antibody Fc conjugates with concomitant ligand release

Read more
October 14, 2024

The First-in-Class Anti-Staphylococcal Antibiotic Afabicin Desphosphono is Not Associated With Clostridioides difficile Infection in an in vitro Human Gut Model

Read more
October 14, 2024

Assessment of Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment for the Anti-Staphylococcal Antibiotic Afabicin

Read more
October 14, 2024

Results from A Phase 2 Clinical Trial for Treatment of Bone And Joint Infections with Afabicin, A First-in-Class Selective Anti-Staphylococcal…

Read more
September 13, 2024

Anti-tumor effect of Debio 0432, a potent and selective USP1 inhibitor, in combination with PARP inhibitors

Read more
September 13, 2024

Debio 0123 + Carboplatin for Patients with Advanced Solid Tumors: Safety, Preliminary Efficacy and Determination of Recommended Phase 2 Dose

Read more
September 13, 2024

Debio 0123, a highly selective WEE1 inhibitor, combined with carboplatin and etoposide in patients with small cell lung cancer that…

Read more
July 19, 2024

Theranostic targeting of CAIX in patients with clear cell renal cell carcinoma: first‑in‑human safety, imaging and dosimetry findings with [68Ga]Ga‑DPI-4452

Read more